

## **Case Study of a Clinical Trial for A Molecular Targeting Anti-Cancer Drug**

Satoshi Morita

*Program in Health and Community Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan*

This talk considers a clinical trial in patients with non-small-cell lung cancer, in particular, in a subgroup of patients with Epidermal Growth Factor Receptor (EGFR) Mutation. Currently, in Japan, a couple of phase II and III trials are underway to examine the efficacy and safety of gefitinib in Asian population of patients. I also discuss an application of a hierarchical modeling approach to evaluation of treatment effects in subpopulations using this example.

[ Satoshi Morita, Program in Health and Community Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan ; smorita@med.nagoya-u.ac.jp]